Clinical Trial Update: Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children [Phase 3]

View source ↗

Summary

Follow-up study update for Viaskin Peanut in children assessing long-term efficacy and safety in peanut allergy (Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Viaskin Peanut (peanut epicutaneous immunotherapy patch)

Snippet

Sponsor: DBV Technologies | Conditions: Peanut Allergy | Phase 3 | Status: UNKNOWN